News
PACB
1.338
-4.46%
-0.063
PacBio cut to Neutral at Goldman Sachs after guidance cut
Goldman Sachs downgraded its recommendation on PacBio to Neutral from Buy. The gene sequencing company lowered its full-year guidance below consensus with its preliminary Q1 results. PacBio cut to Neutral at Goldman Sachs after guidance cut. Analyst Matthew Sykes lowered his rating on the California-based company to Neutral.
Seeking Alpha · 15h ago
Pacific Biosciences Price Target Cut to $8.00/Share From $15.00 by Scotiabank
Dow Jones · 16h ago
Pacific Biosciences Is Maintained at Sector Outperform by Scotiabank
Dow Jones · 16h ago
Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $8
Benzinga · 16h ago
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB) and Eli Lilly & Co (LLY)
TipRanks · 16h ago
U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Builders Firstsource, Eli Lilly, Northern Trust and Abbott Laboratories are among those. Alphabet Inc raises its target price to $165 from $160. 10X Genomics, a maker of DNA sequencing equipment, is downgraded to hold from sell.
Reuters · 20h ago
PACIFIC BIOSCIENCES OF CALIFORNIA INC <PACB.O>: STEPHENS CUTS TARGET PRICE TO $3.50 FROM $9
Reuters · 22h ago
A Glimpse Into The Expert Outlook On Pacific Biosciences Through 4 Analysts
Pacific Biosciences (NASDAQ:PACB) is a biotechnology company focused on genetic analysis. The company has an average 12-month price target of $6.12. Four analysts have shared their insights on Pacific Bioscience in the last three months. The analysts' opinions range from bullish to bearish on the company.
Benzinga · 1d ago
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
NASDAQ · 1d ago
Pacific Biosciences Price Target Cut to $2.50/Share From $12.00 by TD Cowen
Dow Jones · 1d ago
Pacific Biosciences Is Maintained at Buy by TD Cowen
Dow Jones · 1d ago
TD Cowen Maintains Buy on Pacific Biosciences, Lowers Price Target to $2.5
Benzinga · 1d ago
PACIFIC BIOSCIENCES OF CALIFORNIA INC <PACB.O>: SCOTIABANK CUTS TARGET PRICE TO $8 FROM $15
Reuters · 1d ago
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
Shares of INVO Bioscience, Inc. (NASDAQ:INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results. The company said quarterly revenue surged 397% year-over-year to $1,381,754. Mobile Global Esports Inc. Shares gained 36.1% on Tuesday.
Benzinga · 1d ago
U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. 3M, J&J and Nuvalent are among the companies. Analysts also raise their targets on Amazon, Tractor Supply, UnitedHealth Group and Amgen. NEW: 3M cuts its target price to $110 from $118; 10X Genomics cuts target price.
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Alvotech (ALVO) and Pacific Biosciences (PACB)
TipRanks · 1d ago
PACIFIC BIOSCIENCES OF CALIFORNIA INC <PACB.O>: TD COWEN CUTS TARGET PRICE TO $2.5 FROM $12
Reuters · 1d ago
The Cathie Wood Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
Investorplace · 2d ago
S&P 500 Edges Lower; PacBio Shares Plunge
U.S. Stocks traded mixed toward the end of trading on Tuesday. The Dow traded up 0.02% to 37,741.96 while the NASDAQ fell 0.20%. The S&P 500 fell around 0.3% in trading. Information technology shares rose by 0.4% on Tuesday while real estate shares fell by 1.8%. Euro zone European shares closed lower on Tuesday; Asian markets closed lower.
Benzinga · 2d ago
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Sk Skillsoft Corp. Shares dipped 26.7% to $6.74 on Tuesday. The company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. WiSA Technologies, Inc. Shares jumped 85% after the company announced a licensing agreement with an HDTV/PTV brand.
Benzinga · 2d ago
More
Webull provides a variety of real-time PACB stock news. You can receive the latest news about Pacific Biosc through multiple platforms. This information may help you make smarter investment decisions.
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.